Bayer AG - Annual Report 2006 - Phase III study for rivaroxaban under way

Highlights

Phase III study for rivaroxaban under way

Rivaroxaban, a new substance to inhibit blood coagulation, was developed by Dr. Susanne Röhrig and her colleagues in Wuppertal, Germany.

Zoom image

Rivaroxaban, a new substance to inhibit blood coagulation, was developed by Dr. Susanne Röhrig and her colleagues in Wuppertal, Germany.

Leverkusen – Based on positive research findings so far, a phase III study program for rivaroxaban was launched at the end of 2006. Phase II clinical trial results highlighted the potential of a simple, once-daily dosing regimen of the novel, oral anticoagulant rivaroxaban. In this trial, rivaroxaban demonstrated that it may have similar safety and efficacy to the current standard for the prevention of venous thromboembolism ( info

VTE). Present published results also show that rivaroxaban offers predictable anticoagulation across a wide range of parameters. In addition, data show that rivaroxaban does not interact with a wide variety of drugs that are commonly given concomitantly with an anticoagulant. Rivaroxaban is being jointly developed by Bayer HealthCare and Ortho-McNeil Pharmaceuticals Inc., a subsidiary of Johnson & Johnson.